Case Studies

CarboMet - Case Study - The Heparin Contamination Crisis

Case Study 1 – The Heparin contamination crisis (2008)

Heparin is a polysaccharide that interacts with antithrombin in blood and is widely used in the clinic as an injectable anticoagulant, isolated from natural sources. READ MORE

CarboMet - Case Study - Erythropoietin (EPO)

Case Study 2 – Erythropoietin (EPO)

EPO is a glycoprotein hormone that stimulates the production of red blood cells and is used as a therapeutic agent for the treatment of anaemia. READ MORE

CarboMet - Case Study - Erythropoietin (EPO)

Case Study 3 – Bringing HMOs to market –2'-Fucosyllactose

2’-Fucosyllactose (2’-FL) is an oligosaccharide (made up of the 3 sugar units fucose, glucose, and, galactose) and is the most abundant HMO in breast milk. It is believed to play a role in preventing infections by blocking pathogens and toxins. It is of interest as an ingredient for infant formula milk. READ MORE

CarboMet - Case Study - Erythropoietin (EPO)

Case Study 4 - Prevnar and the production of carbohydrate based vaccines

Prevnar is a glycoconjugate vaccine against pneumonia used to fight infections caused by pneumococcal bacteria, and achieved annual sales of approximately $6 billion in 2015. Several variants are now available containing multiple serotypes of pneumococcus e.g. Prevnar 13 containing 13 serotypes. READ MORE

CarboMet on LinkedIn
CarboMet Newsletter Sign Up

CarboMet News

CarboMet on Twitter

European Union flag This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 737395.